Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Capital Expenditures: 2016-2025

Historic Capital Expenditures for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$54,000.

  • Rocket Pharmaceuticals' Capital Expenditures fell 103.40% to -$54,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $669,000, marking a year-over-year decrease of 93.44%. This contributed to the annual value of $5.9 million for FY2024, which is 64.33% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Capital Expenditures of -$54,000 as of Q3 2025, which was down 208.00% from $50,000 recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Capital Expenditures ranged from a high of $4.7 million in Q3 2023 and a low of -$54,000 during Q3 2025.
  • Over the past 3 years, Rocket Pharmaceuticals' median Capital Expenditures value was $1.9 million (recorded in 2024), while the average stood at $2.1 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Capital Expenditures skyrocketed by 2,510.56% in 2021 and then tumbled by 103.40% in 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Capital Expenditures (Quarterly) stood at $2.0 million in 2021, then spiked by 52.82% to $3.0 million in 2022, then spiked by 54.75% to $4.6 million in 2023, then tumbled by 93.35% to $309,000 in 2024, then plummeted by 103.40% to -$54,000 in 2025.
  • Its Capital Expenditures stands at -$54,000 for Q3 2025, versus $50,000 for Q2 2025 and $364,000 for Q1 2025.